Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Amortization of Deferred Charges: 2011-2024

Historic Amortization of Deferred Charges for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $1.2 million.

  • Ptc Therapeutics' Amortization of Deferred Charges rose 1.67% to $305,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 1.93%. This contributed to the annual value of $1.2 million for FY2024, which is 36.04% down from last year.
  • Ptc Therapeutics' Amortization of Deferred Charges amounted to $1.2 million in FY2024, which was down 36.04% from $1.9 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Amortization of Deferred Charges high stood at $22.6 million for FY2020, and its period low was $1.2 million during FY2024.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $1.9 million (2023), whereas its average is $1.7 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first spiked by 87.89% in 2020, then plummeted by 91.82% in 2021.
  • Ptc Therapeutics' Amortization of Deferred Charges (Yearly) stood at $22.6 million in 2020, then slumped by 91.82% to $1.8 million in 2021, then grew by 2.87% to $1.9 million in 2022, then decreased by 1.47% to $1.9 million in 2023, then plummeted by 36.04% to $1.2 million in 2024.